Stock Details
DSKYF is Daiichi Sankyo Company, Limited's stock. Stock exchange Other OTC (Currency USD). Average price in 50 days is 24.74$. Average daily volumn in 3 months 4.46k. Market cap 47.86B



Stock symbol : DSKYF. Exchange : Other OTC. Currency : USD
Lastest price : 24.57$. Total volume : 4.28k. Market state PRE
Click reload if you want to check the lastest price on market!!!

Daiichi Sankyo Company, Limited (DSKYF)
Last Price
24.57$
Change
-1.46
Volume
4.28k

Previous Close26.03
Open24.17
Day Range24.01-25.40
Bid0.00 x N/A
Ask0.00 x N/A
Volume4.28k
Average Volume4.46k
Market Cap47.86B
Beta0.75
52 Week Range17.61-28.93
Trailing P/E94.50
Foward P/E64.66
Dividend (Yield %)0.81%
Ex-Dividend Date2022-09-29



Financial Details


According to Daiichi Sankyo Company, Limited's financial reports the company's revenue in 2022 were 1.04T an decrease( +3.95%) over the years 2021 revenue that were of 962.52B. In 2022 the company's total earnings were 66.97B while total earnings in 2021 were 75.96B(-12%).


Loading ...



Organization

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatm... ent; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Market Cap:
47.86B
Revenue:
1.04T
Total Assets:
2.22T
Total Cash:
662.48B



News about "Daiichi Sankyo Company, Limited"

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Sees Large Decline in Short Interest

Source from : Defense World - 13 days ago

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY โ€“ Get Rating) was the recipient of a large decline in short interest in May. As of May 31st, there was short interest totalling 105,100 shares, a decline ...See details»


Daiichi Sankyo Co. Ltd. ADR

Source from : Wall Street Journal - 5 days ago

1 Day DSNKY 2.65% DJIA 2.68% S&P 500 3.06% Health Care/Life Sciences -1.01% Sunao Manabe President, CEO & Representative Director Daiichi Sankyo Co., Ltd. Hiroyuki Okuzawa CFO, Director ...See details»


Daiichi Sankyo submits sNDA to Japanโ€™s MHLW for trastuzumab deruxtecan to treat patients with HER2 low metastatic breast cancer

Source from : Pharmabiz - 2 days ago

Daiichi Sankyo submits sNDA to Japanโ€™s MHLW for trastuzumab deruxtecan to treat patients with HER2 low metastatic breast cancer: Tokyo Tuesday, June 28, 2022, 16:00 Hrs [IST] Da ...See details»


Daiichi Sankyo Co Ltd - Stock Executive D4S

Source from : Morningstar%2c Inc. - 7 days ago

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.See details»


DSKYF Daiichi Sankyo Company, Limited

Source from : Seeking Alpha - 17 days ago

The chart has 1 X axis displaying Time. Data ranges from 2021-06-10 20:00:00 to 2022-06-14 13:28:52. The chart has 1 Y axis displaying values. Data ranges from -28.09 to 17.56.See details»


japans-five-hottest-biotech-companies-in-healthcare-image

Japanโ€™s five hottest biotech companies in healthcare

Source from : the Top 10 - 15 days ago

While historically lacking in foreign investments, Japanโ€™s biotech scene is now thriving with global investors showing increasing interest. Here are five of the hottest Japanese private companies ...See details»


Daiichi Sankyo doses first person in breast cancer treatment trial

Source from : London South East - 17 days ago

(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in ...See details»


astrazeneca-daiichi-sankyos-enhertu-gets-approval-in-canada-for-breast-cancer-subtype-image

AstraZeneca, Daiichi Sankyo's Enhertu gets approval in Canada for breast cancer subtype

Source from : Seeking Alpha - 7 days ago

Health Canada approved the expanded use of AstraZeneca (AZN) and Daiichi Sankyo's (DSKYF) (DSNKY) Enhertu to treat certain patients with breast cancer.Enhertu (trastuzumab ...See details»


NCLAT Stays Insolvency Proceedings Against RHC Holding

Source from : Businessworld - 24 days ago

The National Company Law Appellate Tribunal ... Later, Sun Pharmaceuticals Ltd acquired Ranbaxy from Daiichi Sankyo. Daiichi Sankyo submitted before the NCLAT that Religare Comtrade Ltd has ...See details»


AstraZeneca to make 90 million COVID-19 doses in Japan

Source from : ๆœๆ—ฅๆ–ฐ่ž็คพ - 4 days ago

The drug company turned to local production to ensure ... will produce the content of the vaccine, while Tokyo-based Daiichi Sankyo Co. and KM Biologics Co., based in Kumamoto Prefecture, will ...See details»


Swing low, sweet Enhertu: Astrazeneca, Daiichi ASCO data carry HER2 message home

Source from : BioWorld - 24 days ago

The โ€œshowdownโ€ at the American Society of Clinical Oncology (ASCO) meeting foreseen by one analyst between breast cancer drugs from Gilead Sciences Inc. and Astrazeneca plc with partner Daiichi Sankyo ...See details»


tropion-breast02-phase-3-trial-of-datopotamab-deruxtecan-initiated-in-patients-with-previously-untreated-metastatic-triple-negative-breast-cancer-image

TROPION-Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer

Source from : Yahoo Finance - 17 days ago

Breast02 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Previously Untreated Metastatic Triple Negative Breast Cancer ...See details»


roquefort-therapeutics-buys-uk-biotech-in-return-for-shares-image

Roquefort Therapeutics buys UK biotech in return for shares

Source from : the Top 10 - 7 days ago

Medical biotechnology company, Roquefort Therapeutics, has conditionally agreed to buy UK biotech Oncogeni Ltd in return for shares.See details»


Global Antibody Drug Conjugates (ADC) Market Research Report 2022 - ResearchAndMarkets.com

Source from : PharmiWeb - 21 days ago

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and ...See details»